Alprostadil in treatment of acute cerebral infarction

AIM: To observe the effect of alprostadil (lipoprostaglandine E 1) in the treatment of acute cerebral infarction. METHODS: Ninety eight patients with acute cerebral infarction were divided into two groups. Alprostadil group ( n =58) [M 32,F 26; age 62 a± s 9 a(46～80 a)] was treated with alprostadil 10 μg, iv, qd for 15. Ligustrazine group ( n =40) [M 24,F 16;age 61 a±9 a(44～82 a)] was treated with ligustrazine 200 mg, iv, gtt, qd, for 15 d. RESULTS: There was a significant difference ( P 0.01) for the nerve function deficiency between the alprostadil group (6.9±2.4) and the ligustrazine group (4.4±1.9) after treatment. Meanwhile, there was a strongly significant difference for the living ability between the alprostadil group (1.7±0.6) and the ligustrazine group (1.5±0.7) after treatment ( P 0.01). CONCLUSION: Alprostadil is an effective drug for decreasing nerve function deficiency and improving living ability in patients with acute cerebral infarction.